194 related articles for article (PubMed ID: 15502972)
1. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.
Goff DC; Herz L; Posever T; Shih V; Tsai G; Henderson DC; Freudenreich O; Evins AE; Yovel I; Zhang H; Schoenfeld D
Psychopharmacology (Berl); 2005 Apr; 179(1):144-50. PubMed ID: 15502972
[TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
Goff DC; Tsai G; Levitt J; Amico E; Manoach D; Schoenfeld DA; Hayden DL; McCarley R; Coyle JT
Arch Gen Psychiatry; 1999 Jan; 56(1):21-7. PubMed ID: 9892252
[TBL] [Abstract][Full Text] [Related]
3. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia.
Evins AE; Amico E; Posever TA; Toker R; Goff DC
Schizophr Res; 2002 Jul; 56(1-2):19-23. PubMed ID: 12084415
[TBL] [Abstract][Full Text] [Related]
4. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
[TBL] [Abstract][Full Text] [Related]
5. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
Goff DC; Tsai G; Manoach DS; Coyle JT
Am J Psychiatry; 1995 Aug; 152(8):1213-5. PubMed ID: 7625475
[TBL] [Abstract][Full Text] [Related]
6. Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study.
Takiguchi K; Uezato A; Itasaka M; Atsuta H; Narushima K; Yamamoto N; Kurumaji A; Tomita M; Oshima K; Shoda K; Tamaru M; Nakataki M; Okazaki M; Ishiwata S; Ishiwata Y; Yasuhara M; Arima K; Ohmori T; Nishikawa T
BMC Psychiatry; 2017 Jul; 17(1):249. PubMed ID: 28701225
[TBL] [Abstract][Full Text] [Related]
7. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia.
Goff DC; Henderson DC; Evins AE; Amico E
Biol Psychiatry; 1999 Feb; 45(4):512-4. PubMed ID: 10071726
[TBL] [Abstract][Full Text] [Related]
8. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
[TBL] [Abstract][Full Text] [Related]
9. Effects of D-cycloserine on negative symptoms in schizophrenia.
Duncan EJ; Szilagyi S; Schwartz MP; Bugarski-Kirola D; Kunzova A; Negi S; Stephanides M; Efferen TR; Angrist B; Peselow E; Corwin J; Gonzenbach S; Rotrosen JP
Schizophr Res; 2004 Dec; 71(2-3):239-48. PubMed ID: 15474895
[TBL] [Abstract][Full Text] [Related]
10. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Tsai G; Lane HY; Yang P; Chong MY; Lange N
Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
[TBL] [Abstract][Full Text] [Related]
11. D-serine added to clozapine for the treatment of schizophrenia.
Tsai GE; Yang P; Chung LC; Tsai IC; Tsai CW; Coyle JT
Am J Psychiatry; 1999 Nov; 156(11):1822-5. PubMed ID: 10553752
[TBL] [Abstract][Full Text] [Related]
12. Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Evins AE; Fitzgerald SM; Wine L; Rosselli R; Goff DC
Am J Psychiatry; 2000 May; 157(5):826-8. PubMed ID: 10784481
[TBL] [Abstract][Full Text] [Related]
13. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Heresco-Levy U; Ermilov M; Shimoni J; Shapira B; Silipo G; Javitt DC
Am J Psychiatry; 2002 Mar; 159(3):480-2. PubMed ID: 11870017
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
[TBL] [Abstract][Full Text] [Related]
15. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
[TBL] [Abstract][Full Text] [Related]
16. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
[TBL] [Abstract][Full Text] [Related]
17. D-alanine added to antipsychotics for the treatment of schizophrenia.
Tsai GE; Yang P; Chang YC; Chong MY
Biol Psychiatry; 2006 Feb; 59(3):230-4. PubMed ID: 16154544
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of adjunctive D-Cycloserine for the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Kuppili PP; Menon V; Sathyanarayanan G; Sarkar S; Andrade C
J Neural Transm (Vienna); 2021 Feb; 128(2):253-262. PubMed ID: 33439362
[TBL] [Abstract][Full Text] [Related]
19. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
Goff DC; Cather C; Gottlieb JD; Evins AE; Walsh J; Raeke L; Otto MW; Schoenfeld D; Green MF
Schizophr Res; 2008 Dec; 106(2-3):320-7. PubMed ID: 18799288
[TBL] [Abstract][Full Text] [Related]
20. D-cycloserine added to clozapine for patients with schizophrenia.
Goff DC; Tsai G; Manoach DS; Flood J; Darby DG; Coyle JT
Am J Psychiatry; 1996 Dec; 153(12):1628-30. PubMed ID: 8942463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
